Seelos in-licenses gene therapy for Parkinson’s; shares ahead 17% premarket

Nano cap Seelos Therapeutics (NASDAQ:SEEL) is up 17% premarket on robust volume in reaction to its licensing deal with Duke University for exclusive rights to a CRISPR-based gene therapy for the potential treatment of Parkinson’s disease (PD).

The candidate, named SLS-004, targets a gene called SNCA which encodes alpha-synuclein expression. Elevated levels of wild-type alpha-synuclein are associated with the development of PD.

Financial terms remain confidential.

https://seekingalpha.com/news/3474227-seelos-licenses-gene-therapy-parkinsons-shares-ahead-17-percent-premarket